ABSTRACT
BACKGROUND Accurately identifying COVID-19 patients at-risk to deteriorate remains challenging. Tools integrating host-protein expression have proven useful in determining infection etiology and hold potential for prognosticating disease severity.
METHODS Adults with COVID-19 were recruited at medical centers in Israel, Germany, and the United States. Severe outcome was defined as intensive care unit admission, non-invasive or invasive ventilation, or death. Tumor necrosis factor related apoptosis inducing ligand (TRAIL) and interferon gamma inducible protein-10 (IP-10; also known as CXCL10) and C-reactive protein (CRP) were measured using an analyzer providing values within 15 minutes. A signature indicating the likelihood of severe outcome was derived generating a score (0-100). Patients were assigned to 4 score bins.
RESULTS Between March and November 2020, 518 COVID-19 patients were enrolled, of whom 394 were eligible, 29% meeting a severe outcome. The signature’s area under the receiver operating characteristic curve (AUC) was 0.86 (95% confidence interval: 0.81-0.91). Performance was not confounded by age, sex, or comorbidities and superior to IL-6 (AUC 0.77; p = 0.033) and CRP (AUC 0.78; p < 0.001). Likelihood of severe outcome increased significantly (p < 0.001) with higher scores. The signature differentiated patients who further deteriorated after meeting a severe outcome from those who improved (p = 0.004) and projected 14-day survival probabilities (p < 0.001).
CONCLUSION The derived immune-protein signature combined with a rapid measurement platform is an accurate predictive tool for early detection of COVID-19 patients at-risk for severe outcome, facilitating timely care escalation and de-escalation and appropriate resource allocation.
FUNDING MeMed funded the study
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf. AK, BT, GD, DD, MSt, MSa, PS declare they have: received no support from any organization for the submitted work; have no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work. AA, EE, ER, ES, KO, MH, MR, NA, NSM, OS, RN, TIB, TMG, and YKI declare they are employees of MeMed, hold stock and/or options and receive salaries. PF declares he holds MeMed stock options. SL declares to have received lecturing fees from MeMed. EE, ES, KO, MH, NSM, OS, RN, SL, TIB, TMG declare they are authors of pending or issued patent applications relating to the submitted work. AJ, EBS, IK, KR, SM, IK declare that their medical center received funding from MeMed for the described clinical study. CP declares to have received a research grant from MeMed.
Funding Statement
MeMed funded the clinical study described in the manuscript. MeMed provided the measurement platforms and consumables.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Maimonides Medical Center, New York, US, IRB#: 2020-05-21 Saarland University Medical Center, Homburg, Germany, IRB#: 1009-20 Hillel Yaffe Medical Center, Hadera, Israel, IRB#: 0059-15 Shaare Zedek Medical Center, Jerusalem, Israel, IRB#: 0313-20 Beilinson Medical Center, Petah Tikva, Israel, IRB#: 0257-20 Hasharon Medical Center, Petah Tikva, Israel, IRB#: 0257-20
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
